Erratum: Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors (Clinical Pharmacokinetics (2012) 51:8 (501-514) DOI: 10.2165/11632930-000000000-00000);Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

Clinical Pharmacokinetics

Volumn 51, Issue 8, 2012, Pages 501-514

  Golightly, Larry K ^a,b   Drayna, Caitlin C ^b   McDermott, Michael T ^a,c  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

alogliptin; CD26 antigen inhibitors; linagliptin; pharmacokinetics; saxagliptin; sitagliptin; type 2 diabetes mellitus; vildagliptin

Indexed keywords

ALOGLIPTIN; ALUMINUM HYDROXIDE; AMPRENAVIR; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DAPAGLIFLOZIN; DIGOXIN; DILTIAZEM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ERYTHROMYCIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FAMOTIDINE; FLUCONAZOLE; GEMFIBROZIL; GLIBENCLAMIDE; KETOCONAZOLE; LINAGLIPTIN; MAGNESIUM HYDROXIDE; METFORMIN; PIOGLITAZONE; RIFAMPICIN; ROSIGLITAZONE; SAXAGLIPTIN; SIMETHICONE; SIMVASTATIN; SITAGLIPTIN; UNINDEXED DRUG; VILDAGLIPTIN; WARFARIN;

AREA UNDER THE CURVE; BILIARY EXCRETION; COMORBIDITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TRANSFORMATION; EVENING DOSAGE; HUMAN; INTESTINE ABSORPTION; LIPOPHILICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

EID: 84863436536     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-012-0019-4     Document Type: Erratum

References (141)

1. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954-62
2. McIntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 1965; 25: 1317-24
3. Elrick H, Stimmler L, Hlad Jr CJ, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076-82
4. Dupré J. An intestinal hormone affecting glucose disposal in man. Lancet 1964; 2: 672-3
5. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-8 (Pubitemid 16035703)
6. Nauck M, Stö ckmann F, Ebert R, et al. Reduced incretin effect in type 2 (noninsulin-dependent) diabetes. Diabetologia 1986; 29: 46-52 (Pubitemid 16162741)
7. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-206 (Pubitemid 38943883)
8. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-39 (Pubitemid 350041474)
9. Bagger JI, Knop FK, Lund A, et al. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 737-45
10. Holst JJ, Krarup T, Knop FK, et al. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011; 34 Suppl. 2: S251-7
11. Hare KJ, Vilsbøll T, Asmar M, et al. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010; 59: 1765-70
12. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-20 (Pubitemid 28084232)
13. Waget A, Cabou C, Masseboeuf M, et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 2011; 152: 3018-29
14. Marchetti C, Di Carlo A, Facchiano F, et al. High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia 2012; 55: 236-44
15. Duttaroy A, Voelker F, Merriam K, et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur J Pharmacol 2011; 650: 703-7
16. Foley JE, Bunck MC, Mö ller-Goede DL, et al. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 weeks washout without in drug-na?̈ve patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 2011; 54: 1985-91
17. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205 (Pubitemid 46206563)
18. Pospislilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates b-cell survival and islet neogenesis in streptozotocininduced diabetic rats. Diabetes 2003; 52: 741-50 (Pubitemid 36323582)
19. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64: 562-76
20. Van Genugten RE, Van Raalte DH, Daimant M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes Metab 2012; 14: 101-11
21. Zhang X, Wang Z, Huang Y, et al. Effects of chronic administration of alogliptin on the development of diabetes and b-cell function in high fat diet/streptozotocin diabetic mice. Diabetes Obes Metab 2011; 13: 337-47
22. Chen B, Moore A, Escobedo LVS, et al. Sitagliptin lowers glucagon and improves tolerance in prediabetic SHROB rats. Exp Biol Med 2011; 236: 309-14
23. Migoya EM, Bergeron R, Miller JL, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010; 88: 801-8
24. Dobrian AD, Ma Q, Lindsay JW, et al. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab 2011; 300: E410-21
25. Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011; 60: 1246-57
26. Miura K, Kitahara Y, Yamagishi S. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats. Horm Metab Res 2010; 42: 731-5
27. Matikainen N, Mä nttari S, Schweizer A, et al. Vildagliptin therapy reduces intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 2047-57
28. Mason RP, Jacob RF, Kubant R, et al. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb 2011; 18: 774-83
29. Lamanna C, Monami M, Bartoli N, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular events: a protective effect? [abstract]. European Association for the Study of Diabetes (EASD) 47th Annual Meeting. Lisbon, Portugal: September 20, 2011 [online]. Available from URL: http://www. abstractsonline.com/Plan/ViewAbstract.aspx?sKey=2f88f1ba-1c6c-4863-95 21-2def7b443f46&cKey=48d7640c-6588-4847-916d-fbce529f98eb&mKey=% 7BBAFB2746-B0DD-4110-8588-E385FAF957B7%7D [Accessed 2011Nov 8]
30. Kühn-Wache K, Bä r JW, Hoffmann T, et al. Selective inhibition of dipeptidyl peptidase 4 by targeting a substrate-specific secondary binding site. Biol Chem 2011; 392: 223-31
31. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-248
32. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011; 34 Suppl. 2: S279-84
33. Monami M, Marchionni N, Mannuchi E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009; 160: 909-17
34. Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized and clinical trials. Exp Diabetes Res 2011; 2011: 215674
35. Faknoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010; 86: 44-57
36. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; (2): CD006739
37. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011; 13: 7-18
38. Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of
39. Monami M, Cremasco F, Lamanna C, et al. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev 2011; 27: 362-72
40. Januvia tablets [package insert]. Whitehouse Station (NJ): Merck&Co. Inc.,
41. Onglyza tablets [package insert]. Princeton (NJ):Bristol-Myers Squibb Co., 2009
42. Tradjenta tablets [package insert]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals Inc., 2011
43. European Medicines Agency. Galvus: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000771/WC5000 20327.pdf [Accessed 2012 Feb 28]
44. European Medicines Agency. Januvia: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000722/WC5000 39054.pdf [Accessed 2011 Oct 13]
45. European Medicines Agency. Onglyza: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Infsormation/human/001039/WC5000 44316.pdf [Accessed 2011 Oct 13]
46. European Medicines Agency. Trajenta: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/002110/WC5001 15745.pdf [Accessed 2011 Nov 7]
47. Ogata S, Misumi Y, Ikehara Y. Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of theNH2-terminal signal sequence as the membrane-anchoring domain. J Biol Chem 1989; 264: 3596-501
48. Vilsbøll T, Agersø H, Krarup T, et al. Similar elimination rates of glucagonlike peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88: 220-4 (Pubitemid 36115169)
49. Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes Vasc Dis Res 2006; 3: 159-65 (Pubitemid 44902481)
50. Lambeir A-M, Scharpé S, DeMeester I. DPP4 inhibitors for diabetes: what's next? Biochem Pharmacol 2008; 76: 1637-43
51. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011; 71: 1441-67
52. Lambeir A-M, Durinx C, Scharpé S, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40: 209-94 (Pubitemid 36775376)
53. Oefner C, D'Arcy A, MacSweeney A, et al. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5- iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S)-pyrollidine. Acta Crystallogr D Biol Crystallogr 2003; 59: 1206-12 (Pubitemid 36872357)
54. Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2010; 90: 131-40
55. Gupta R, Walunj SS, Tokala RK, et al. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 diabetes. Curr Drug Targets 2009; 10: 71-87
56. Kirby M, Yu DMT, O'Connor SP, et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci 2010; 118: 31-41
57. Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007; 50: 2297-300 (Pubitemid 46799241)
58. Thomas L, Eckhardt M, Langkopf E, et al. (R)-8-(3-amino-piperidin-1-yl)- 7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008; 325: 175-82 (Pubitemid 351439162)
59. Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7- but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007; 50: 6450-3 (Pubitemid 350309082)
60. Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 5025-7
61. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[ 1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 141-51 (Pubitemid 40105255)
62. Kim YB, Kopcho LM, Kirby MS, et al. Mechanism of Gly-Pro-pNAcleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Arch Biochem Biophys 2006; 445: 9-18 (Pubitemid 41821056)
63. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-9 (Pubitemid 44833446)
64. Herman GA, Stein PP, Thornberry NA, et al. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007; 81: 761-7 (Pubitemid 46625120)
65. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl) amino)acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 16: 2774-89 (Pubitemid 36702545)
66. Brandt I, Joossens J, Chen X, et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3-hydroxyadamantan-1- yl) amino]acetyl}-pyrrolidine-2-carbonitrile).Biochem Pharmacol 2005; 70: 134-43 (Pubitemid 40797877)
67. Coughlan A, McCarty DJ, Jorgensen LN, et al. The epidemic of NIDDM in Asian and Pacific Island populations: prevalence and risk factors. Horm Metab Res 1997; 29: 323-31
68. Kawamori R. Diabetes trends in Japan. Diabetes Metab Res Rev 2002; 18 Suppl. 3: S9-13 (Pubitemid 35256578)
69. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and prevention strategies [published erratum appears in Lancet 2004; 363 (9412): 902]. Lancet 2004; 363: 902
70. Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008; 30: 513-27 (Pubitemid 351492530)
71. Christopher R, Karim A. Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. Expert Rev Clin Pharmacol 2009; 2: 589-600
72. Hirayama M, Matsuno K, Fujita T, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects [abstract no. 521]. Diabetes 2008; 57 Suppl. 1: A155
73. Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010; 70: 2051-72
74. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multipledose study in adult patients with type 2 diabetes. Clin Ther 2008; 30: 499-512 (Pubitemid 351483925)
75. Sarashina A, Sesoko S, Nakashima M, et al. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther 2010; 32: 1188-204
76. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, et al. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010; 38: 667-78
77. Retlich S, Duval V, Ring A, et al. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clin Pharmacokinet 2010; 49: 829-40
78. Forst T, Uhlig-Laske B, Ring A, et al. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13: 542-50
79. Heise T, Graefe-Mody EU, Hü ttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009; 11: 786-94
80. Horie Y, Kanada S, Watada H, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. Clin Ther 2011; 33: 973-89
81. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011; 50: 253-65
82. Patel CG, Zhang J, Li L, et al. Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects. J Clin Pharmacol 2010; 50: 1211-6
83. BoultonDW, Smith CH, Li L, et al. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and single-component saxagliptin and metformin XR tablets in healthy subjects. Clin Drug Investig 2011; 31: 619-30
84. Vincent SH, Reed JR, Bergman AJ, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007; 35: 533-8 (Pubitemid 46513255)
85. Bergman A, Ebel D, Liu F, et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 2007; 28: 315-22 (Pubitemid 47439637)
86. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 75-88
87. Bergman AJ, Stevens C, Zhao YY, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28: 55-72 (Pubitemid 43254990)
88. Herman GA, Mistry GC, Yi B, et al. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. Br J Clin Pharmacol 2011; 71: 429-36
89. He Y-L, Sadler BM, Sabo R, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007; 46: 787-802 (Pubitemid 47347450)
90. He H, Tran P, Yin H, et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009; 37: 536-44
91. He Y-L, Valencia J, Zhang Y, et al. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes. Br J Clin Pharmacol 2010; 70: 34-42
92. He Y-L, Yamaguchi M, Ito H, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Ther 2010; 48: 582-95
93. Karim A, Covington P, Christopher R, et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase crossover study in healthy subjects. Int J Clin Pharmacol Ther 2010; 48: 46-58
94. Sunkara G, Sabo R, Wang Y, et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol 2007; 47: 1152-8
95. Greischel A, Binder R, Baierl J. The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time-and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats. Drug Metab Dispos 2010; 38: 1443-8
96. Fuchs H, Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos 2009; 30: 229-40
97. Retlich S, Withopf B, Breischel A, et al. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356): investigations in DPP-4 deficient and wildtype rats. Biopharm Drug Dispos 2009; 30: 422-36
98. Retlich S, Duval V, Graefe-Mody U, et al. Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP4 inhibition in type 2 diabetic patients. J Clin Pharmacol 2010; 50: 873-85
99. Deacon CF, Holst JJ. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009; 26: 488-99
100. He Y-L, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007; 46: 577-88 (Pubitemid 47025358)
101. Chu X-Y, Bleasby K, Yabut J, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007; 321: 673-83 (Pubitemid 46624514)
102. Karim A, Fleck P, Hetman L, et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment [abstract no. 538-P]. Diabetes 2008; 57 Suppl. 1: A160
103. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-46
104. Bergman AJ, Smith W, Cote J, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007; 30: 1862-4 (Pubitemid 47036366)
105. Chan JCN, Scott R, Arjona Ferreira AC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008; 10: 549-55
106. Migoya EM, Stevens CH, Bergman AJ, et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009; 16: e165-70
107. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006; 46: 876-86 (Pubitemid 44050824)
108. He Y-L, Sabo R, Campestrini J, et al. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol 2007; 65: 338-46
109. He YL, Flannery B, Wang Y, et al. The influence of renal impairment on the pharmacokinetics of vildagliptin [abstract no. PIII-86]. Clin Pharmacol Ther 2007; 81 Suppl. 1: S113
110. He Y-L, Sabo R, Campestrini J, et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol 2007; 63: 677-86 (Pubitemid 46911348)
111. Lukashevich V, Schweizer A, Shao Q, et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011; 13: 947-54
112. Banerji MA, Purkayastha D, Francis BH. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes Res Clin Pract 2010; 90: 182-90
113. Ito M, Abe M, Okada K, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 2011; 58: 979-87
114. Ligueros-Saylan M, Foley JE, Schweizer A, et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase II and III clinical trials. Diabetes Obes Metab 2010; 12: 495-509
115. Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011; 65: 1230-9
116. Krishnarajah G, Dezil C, Tran M, et al. Evaluation of sitagliptin dosing among renal impaired type 2 diabetes patients [abstract no. PDB70]. Value Health 2010; 13: A67
117. McFarland MS, Cross LB, Gross B, et al. Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic. J Manag Care Pharm 2009; 15: 563-7
118. Quasem M, Liu Y. Acute interstitial nephritis associated with sitagliptin use [abstract no. 257]. Am J Kidney Dis 2011; 57 (4): A81
119. Lestner JM, Baburaj R, Edwards CMB. Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity? Br J Hosp Med 2011; 72: 412-3
120. Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 2008; 25: 1229-30
121. Patel CG, Li L, Girgis S, et al. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol Adv Appl 2011; 2: 13-25
122. Dhillon S, Weber J. Saxagliptin. Drugs 2009;69: 2103-14
123. DiGregorio RV, Pasikova Y. Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. Pharmacotherapy 2009; 29: 352-6
124. Bhome R, Penn H. Rhabdomyolysis precipitated by a sitagliptin- atorvastatin drug interaction. Diabet Med 2012; 29: 693-4
125. PratleyRE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 2009; 10: 503-12
126. Karim A, Laurent A, Munsaka M, et al. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol 2009; 49: 1210-9
127. Friedrich C, Ring A, Brand T, et al. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet 2011; 36: 17-24
128. Friedrich C, Port A, Ring A, et al. Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multipledose study. Clin Drug Investig 2011; 31: 643-53
129. Graefe-Mody U, Rose P, Ring A, et al. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Drug Metab Pharmacokinet 2011; 26: 123-9
130. Graefe-Mody EU, Jungnik A, Ring A, et al. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. Int J Clin Pharmacol Ther 2010; 48: 652-61
131. Upreti VV, Boulton DW, Li L, et al. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol 2011; 72: 92-102
132. Krishna R, Bergman A, Larson P, et al. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl pepitdase-4 inhibitor, in healthy male subjects. J Clin Pharmacol 2007; 47: 165-74 (Pubitemid 46146482)
133. Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 2011; 13: 47-54
134. Mistry GC, Bergman AJ, Zheng W, et al. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol 2008; 66: 36-42 (Pubitemid 351822149)
135. Mistry GC, Bergman AJ, Luo W-L, et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol 2007; 47: 159-64 (Pubitemid 46146481)
136. Bergman AJ, Cote J, Maes A, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol 2009; 49: 483-8
137. Odegaard D, Lane J, StevensRB. Sitagliptin use in kidney transplant recipients: effect on antidepressant levels [abstract]. Diabetes 2009; 58 Suppl.: A1
138. Wright DH, Herman GA, Maes A, et al. Multiple doses of sitagliptin, a
139. He Y-L, Ligueros-Saylan M, Sunkara G, et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has not pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol 2008; 48: 85-95 (Pubitemid 350292271)
140. Scheen AJ, Charpentier G,Ö stgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010; 26: 540-9
141. Signorovitch JE, Wu EQ, Swallow E, et al. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clin Drug Investig 2011; 31: 665-74